Sera Prognostics, Inc.
SERANASDAQHealthcareMedical Devices

About Sera Prognostics

Sera Prognostics, Inc., a women’s health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother’s risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Company Information

CEOZhenya Lindgardt
Founded2008
IPO DateJuly 15, 2021
Employees64
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock
Share ClassClass A Shares

Contact Information

Phone801 990 0520
Address
2749 East Parleys Way, Suite 200 Salt Lake City, Utah 84109 United States

Corporate Identifiers

CIK0001534969
CUSIP81749D107
ISINUS81749D1072
EIN26-1911522
SIC8071

Leadership Team & Key Executives

Zhenya Lindgardt M.B.A.
President, Chief Executive Officer and Director
Dr. John J. Boniface Ph.D.
Chief Scientific Officer
Dr. Gregory C. Critchfield M.D., M.S.
Executive Director
Austin Aerts
Chief Financial Officer
Robert G. Harrison
Chief Information Officer
Jennifer Zibuda
Head of Investor Relations
Benjamin G. Jackson J.D.
General Counsel
Lee Anderson
Chief Commercial Officer
Chuck Hyde
Head of Market Access
Dr. Tiffany Inglis FACOG, M.D.
Chief Medical Officer